RAS's cloak of invincibility slips at last?

Abstract

KRAS is the most frequently activated oncogene in human cancer, but it has, so far, shrugged off all attempts to inhibit its function directly. However, a recent report provides an entirely new approach to blocking mutant KRAS with small molecules and has the added benefit of sparing the wild-type protein.